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ABSTRACT
Peripheral blood T cells were isolated from 19 allogeneic and 4 autologous stem cell transplant (SCT)
recipients and assessed for tumor necrosis factor (TNF)– and interferon (IFN)– transcription by reverse
transcription-polymerase chain reaction. Levels were compared with resting donor T-cell transcription levels.
Increased production of TNF- predicted for the onset of severe (grade II-IV) graft-versus-host disease
(GVHD) (P  .001). Increased TNF- (P  .025) and IFN- (P  .001) transcription also independently
predicted for the eventual onset of extensive chronic GVHD. Increased TNF- or IFN- transcription was not
seen in either a syngeneic SCT recipient or 4 autologous SCT controls. These findings provide a means by
which GVHD can be predicted before it is clinically evident, thus allowing for accurate diagnosis and
monitoring of GVHD and possibly more cost-effective management of post-SCT immunosuppression.
© 2005 American Society for Blood and Marrow Transplantation
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Allogeneic stem cell transplantation (SCT) can
ure malignant and inherited hematologic diseases but
s signiﬁcantly limited by the risk of graft-versus-host
isease (GVHD) [1]. Damage to host tissues caused by
lloreactive T cells contained within the graft is
aused by a variety of mechanisms, including cell con-
act–dependent apoptosis via Fas/Fas ligand, the gran-
yme/perforin pathway, or both [2-6] and cell con-
act–independent inﬂammatory cytokines, including
umor necrosis factor (TNF)– and interferon (IFN)–.
hese cytokines have long been associated with the de-
elopment of and mortality from GVHD [7-10]. In
linical allogeneic SCT, monitoring of TNF-, either in
erum or blood leukocytes, has previously demonstrated
correlation with the severity of GVHD but has not
een able to prospectively predict its onset [6,11]. t
06In patients who survive the risks of acute GVHD,
hronic GVHD can subsequently ensue; it also results
n signiﬁcant morbidity and mortality. The association
etween cytokine production patterns and the onset of
hronic GVHD is less well established, although
ouse models of GVHD using IFN- gene knockout
onors result in a chronic GVHD–like syndrome [12],
nd polymorphisms resulting in decreased IFN- pro-
uction have been associated with an increased risk of
hronic GVHD [13]. Conversely, increased IFN-
roduction by donor CD8 T cells is correlated with
he onset of renal cell carcinoma regression and the
nset of extensive chronic GVHD in nonmyeloabla-
ive allogeneic SCT [14].
Despite the central role of cytokines in the patho-
enesis of GVHD, no real-time diagnostic or moni-
oring measure exists to detect those at imminent risk
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Prospective Monitoring of TNF- and IFN-
Bf GVHD. Consequently, GVHD prophylaxis with
road-spectrum immunosuppression is universally ad-
inistered and results in a signiﬁcant risk of oppor-
unistic infections and other toxicities. Despite
VHD prophylaxis, 40% to 60% of sibling donor
ransplant recipients and 70% of unrelated donor
ransplant recipients develop grade II or greater acute
VHD, the diagnosis of which is based on a combi-
ation of clinical symptoms and signs supported by
issue biopsy of the affected organs, without the aid of
speciﬁc diagnostic test. As a result, GVHD is often
ell established (and, therefore, more resistant to
herapy) before immunosuppression alterations can be
ffected.
We hypothesized that changes in cytokine tran-
cription by engrafted donor T cells would predate the
linical onset of GVHD. We prospectively collected
nd batch-analyzed the transcription of TNF- and
FN- by reverse transcription-polymerase chain re-
ction (PCR) in 23 patients undergoing SCT. In-
reased TNF- and IFN- transcription indepen-
ently predicted for the onset of acute GVHD and
redated its onset by 2 to 20 days. Conversely, an
ncrease in IFN- transcription, but not TNF- tran-
cription, predicted for the development of extensive
hronic GVHD.
ATERIALS AND METHODS
atients
All patients underwent SCT at the Wellington
ancer Centre. The study protocol was approved by
he Wellington Hospital ethics committee, and all
atients gave written informed consent.
Patient details are given in Table 1. A total of 23
atients were enrolled (19 allogeneic SCT and 4 au-
ologous SCT). Autologous SCT recipients were in-
luded as controls for the possible confounding effects
f pre-SCT conditioning and pancytopenia. Two of
he allogeneic SCT patients received nonmyeloabla-
ive conditioning. Five of the allogeneic SCTs were
rom HLA-matched unrelated donors. All 14 sibling
CTs were fully HLA matched except for 1 patient,
ho had a low-resolution mismatch at HLA-A. Mar-
ow alone was used in 5 allogeneic SCTs, and granu-
ocyte colony-stimulating factor–mobilized peripheral
lood progenitor cells (PBPCs) were used in 13. A
ombination of marrow and PBPCs was used in 1
atient. All autograft patients received PBPCs mobi-
ized with a combination of granulocyte colony-stim-
lating factor and cyclophosphamide.
GVHD prophylaxis consisted of cyclosporine 3
g/kg intravenously from day 1 and methotrexate
0 mg/m2 on days 1, 3, 6, and 11 in all allografts, with
he addition of prednisone from day 14 in 11 patients,
s published by Ruutu et al. [15]. T
B&MTAllograft recipients received anti-infective pro-
hylaxis with ﬂuconazole and acyclovir until stable
ngraftment, at which time ganciclovir and co-trimox-
zole prophylaxis was started. In the absence of
ytomegalovirus reactivation, ganciclovir was discon-
inued at day 84 after SCT, and acyclovir was contin-
ed until 12 months after SCT. Autograft recipients
eceived anti-infective prophylaxis with ﬂuconazole
nd acyclovir until engraftment. All allograft recipi-
nts and recipients of autografts previously treated
ith ﬂudarabine-containing regimens received ongo-
ng co-trimoxazole prophylaxis until 12 months after
CT. Allograft patients were clinically assessed for
VHD onset on a minimum of 3 days per week until
ay 100 and weekly until 6 months after SCT. Au-
ograft patients were reviewed weekly until day 100
nd then monthly until 6 months after SCT.
The onset of acute and chronic GVHD was diag-
osed by using clinical and histopathologic assess-
ent. The severity of acute and chronic GVHD was
raded by standard criteria [16]. All patients with
uspected gut GVHD underwent gastroscopy,
olonoscopy, or both to exclude other pathologies and
o conﬁrm GVHD on mucosal biopsy. All patients
ith suspected skin GVHD underwent conﬁrmatory
kin biopsy. Liver biopsy was performed in patients
ith persistent, severe liver dysfunction. In 1 patient
patient 2), the onset of mild oral and hepatic acute
VHD was associated with the onset of nephrotic
yndrome due to biopsy-proven glomerulonephritis.
his previously published case [17] is listed as renal
VHD in Table 2.
Acute GVHD was treated with the addition of
rednisone 2 mg/kg/d and maintenance of cyclospor-
ne levels, with intravenous cyclosporine if enteral
bsorption was impaired. Patients intolerant of cyclo-
porine were changed to mycophenolate mofetil. An-
ithymocyte globulin was used in 1 patient with steroid-
nresponsive gut GVHD. Three patients with severe
kin GVHD received psoralen and UV-A therapy.
amples
Donor samples either of anticoagulated peripheral
lood or an aliquot of apheresis product before SCT
ere taken on day 0. Samples of 10 mL of peripheral
lood were then collected from each patient into eth-
lenediaminetetraacetic acid every 10 days beginning
0 days after SCT. From each sample, T lymphocytes
ere puriﬁed (95% purity) from 10 mL of each
eripheral blood sample with RosetteSep T-cell enrich-
ent cocktail (StemCell Technologies, Vancouver,
anada).
reparation of Complementary DNA
RNAwas isolated immediately from 5 105 isolated
cells by using the RNAqueous RNA-extraction kit
707
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7Ambion, Austin, TX). Seven microliters of RNA was
reated with 2 U of deoxyribonuclease (Invitrogen,
arlsbad, CA) according to the manufacturer’s protocol
o eliminate any genomic DNA contamination. Total
rst-strand complementary DNA (cDNA) was syn-
hesized by using 2.5 mol/L random hexamer prim-
rs, 0.5 mmol/L deoxynucleotide triphosphate solu-
ion, 2 U/L ribonuclease out (Invitrogen), 0.01
ol/L dithiothreitol (supplied with reverse transcrip-
ase), and 10 U/L Moloney murine leukemia virus
everse transcriptase (Invitrogen), according to the
anufacturer’s instructions. A cDNA sample was
ade with no reverse transcriptase as a control for
resence of genomic DNA.
eal-Time PCR to Quantify Cytokine
essenger RNA
At each time point, the cytokine cDNA produced
rom isolated T cells was quantiﬁed by using real-time
uantitative PCR on an ABI Prism 7700 sequence
etection system (Applied Biosystems, Foster City,
A). Cytokine (TNF- and IFN-) cDNA was quan-
iﬁed with Assays on Demand predesigned FAM-la-
eled probe and primer sets from Applied Biosystems
TNF- gene-expression assay no. Hs00174128_m1;
FN- gene-expression assay no. Hs00174143_m1).
ibosomal 18S cDNA was quantiﬁed by using prede-
eloped assay reagent (PDAR) primer and limited
able 1. Clinical Characteristics of Transplant Recipients
Patient No. Sex/Age (y) Disease Conditioning
1 M/34 AML Bu/Cy
2 F/48 AML Cy/TBI
3 F/42 CML Bu/Cy
4 M/39 RCC Flu/Cy
5 M/53 CML Cy/TBI
6 F/51 MDS Flu/Mel
7 M/38 AML Flu/Mel
8 M/51 RCC Flu/Cy
9 M/44 ALL Cy/TBI
0 F/41 ALL Cy/TBI
1 F/33 AML Cy/TBI
2 M/54 MDS Flu/Mel
3 M/45 AML Bu/Cy
4 M/38 AML Bu/Cy
5 F/41 CML Bu/Cy
6 M/25 AML Cy/TBI
7 F/33 ALL Cy/TBI
8 M/58 AML Bu/Cy
0 F/51 AML Bu/Cy
9 F/62 MM Mel
1 M/45 NHL BEAM
2 M/50 MM Mel
3 M/53 MM Mel
ML indicates acute myeloblastic leukemia; CML, chronic myeloid
ALL, acute lymphoblastic leukemia; MM, multiple myeloma; NH
total body irradiation; Flu, ﬂudarabine; Mel, melphalan; BE
progenitor cells; Auto, autologous; MUD, matched unrelated
applicable; CR, complete remission; MOF, multiorgan failure;redesigned VIC-labeled probe and primer sets from 
08pplied Biosystems. PCR reactions were performed in
riplicate in optical 96-well plates in a total volume of
5 L. Each reaction contained 2 L of cDNA, 12.5
L of ABsolute QPCR ROX (500 nmol/L) Mix (AB-
ene, Epsom, UK), 1.25 L of 20 cytokine primer/
robe mix, and 1.25 L of 20 18S PDAR. Tem-
late-free controls were included in each run.
18S PDAR was used to amplify the no-reverse-
ranscriptase control to check for the presence of any
ontaminating DNA in the RNA sample. No contam-
nating genomic DNA was detected in any cDNA
sed for analysis. Thermal cycling conditions were 1
ycle of 95°C for 10 minutes and then 40 cycles of
5°C for 15 seconds, followed by a 60°C annealing/
xtension step for 1 minute. Cytokine cDNA was
ormalized by comparing the amount of 18S cDNA
etween samples. To calculate the relative gene ex-
ression, we used the comparative delta threshold
ycle gene expression method. Cytokine cDNA was
uantiﬁed relative to the amount of cytokine cDNA
ound in the day 0 sample from the donor. An increase
n TNF- or IFN- transcription of 1.5-fold that
resent in the day 0 donor sample was considered as
ositive for increased transcription, as previously de-
cribed [6].
tatistical Analysis
Patient results were analyzed by calculation of the
m Cell Source GVHD Prophylaxis Outcome
ling marrow CSA/MTX Alive CR 36 mo
ling PBPCs CSA/MTX/P Died PD 15 mo
ling marrow CSA/MTX/P Alive CR 28 mo
ling marrow CSA/MTX/P Died PD 3 mo
D marrow CSA/MTX Died GVHD 9 mo
D PBPCs CSA/MTX/P Alive CR 22 mo
ling PBPCs CSA/MTX/P Alive CR 20 mo
ling PBPCs CSA/MTX Alive CR 19 mo
ling marrow CSA/MTX Alive CR 19 mo
D PBPCs CSA/MTX/P Alive CR 15 mo
D PBPCs CSA/MTX Died MOF 3 wk
ling PBPCs CSA/MTX/P Alive CR 14 mo
ling PBPCs CSA/MTX/P Alive CR 12 mo
ling PBPCs CSA/MTX/P Alive CR 12 mo
ling PBPCs CSA/MTX/P Alive CR 11 mo
ling PBPCs CSA/MTX/P Alive CR 10 mo
D PBPCs CSA/MTX/P Alive CR 10 mo
geneic PBPCs NA Died PD 3 mo
ling PBPCs CSA/MTX/P Alive CR 8 mo
to PBPCs NA
to PBPCs NA
to PBPCs NA
to PBPCs NA
mia; RCC, renal cell carcinoma; MDS, myelodysplastic syndrome;
-Hodgkin lymphoma; Bu, busulphan; Cy, cyclophosphamide; TBI,
CNU/etoposide/cytarabine/melphalan; PBPCs, peripheral blood
CSA, cyclosporine; MTX, methotrexate; P, prednisone; NA, not
ogressive disease.Ste
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Prospective Monitoring of TNF- and IFN-
Bhe onset of acute GVHD or increased TNF- or
FN- transcription before the onset of chronic exten-
ive GVHD. Statistical signiﬁcance was set at P 	 .05.
ESULTS
atient Outcome
A total of 22 patients were available for analysis.
ne patient (patient 11) died of multiorgan failure in
he absence of GVHD on day 21. All remaining pa-
ients completed sample collection either until the
nset of GVHD or until day 200 after SCT. Details of
VHD onset and location and patient outcomes are
iven in Table 2. Overall, 9 (50%) of 18 assessable
llograft recipients developed grade II to IV acute
VHD. Of the remaining 9 allograft patients, 6 de-
eloped grade I GVHD. The median time to acute
VHD onset was 60 days (range, 14-123 days).
One patient died of progressive renal carcinoma at
months after SCT. This patient had previously de-
eloped grade III acute gut GVHD. The remaining 17
llograft recipients assessable for the onset of chronic
VHD have been followed up for a median of 15
onths (range, 8-36 months). Eleven (65%) of 17
atients have developed extensive chronic GVHD
able 2. Distribution, Severity, and Time of Onset of GVHD and Cha
nd Syngeneic/Autologous Transplantation
Patient
No.
Grade of
Acute GVHD
Day of Acute
GVHD Onset
Main Site of
Acute GVHD
Inc
T
(F
llografts
1 I 19 Skin
2 III 123 Renal
3 III 79 Gut
4 III 40 Gut
5 IV 62 Skin/liver
6 I 64 Oral
7 IV 65 Gut
8 0 — —
9 III 20 Gut
10 I 63 Skin
11 NA NA NA
12 II 39 Gut
13 I 60 Skin
14 0 — —
15 III 52 Gut
16 0 — —
17 III 14 Skin
20 0 — —
yngeneic and
autografts
18 0 — —
19 NA — —
21 NA — —
22 NA — —
23 NA — —
he fold increases in TNF- and IFN- transcription are for the
A indicates not applicable; NR, not reported.Table 2). A typical time course for TNF- and i
B&MTFN- changes after SCT and the relationship to the
nset of severe GVHD are shown for patient 7 in
igure 1.
NF- Transcription
TNF- transcription analysis was performed in all
2 assessable patients (17 allografts, 1 syngeneic trans-
lant, and 4 autografts). The detection of a 1.5-fold
ncrease in TNF- transcription predicted for the
nset of acute GVHD in 8 of 9 allogeneic SCT re-
ipients who developed grade II or higher acute
VHD (P 	 .001). Increased TNF- transcription
as not detected in any of the 8 allograft recipients
ho did not develop severe acute GVHD, in the
yngeneic SCT recipient, or in 4 autologous SCT
atients. The positive predictive value of an increase
n TNF- transcription for acute GVHD in allograft
atients (excluding the 1 syngeneic recipient) was
00%. Increased TNF- predicted for the onset of
xtensive chronic GVHD in 7 of 11 allogeneic SCT
ecipients who developed grade II or higher acute
VHD (P 	 .025). The negative predictive value of no
ncrease in TNF- transcription in allograft recipients
as 89%. In the allograft recipients who developed ex-
ensive chronic GVHD, the positive predictive value of
Cytokine Transcription in Patients after Allogeneic Transplantation
TNF-
iption
rease)
Day TNF
Detected
Increased IFN-
Transcription
(Fold Increase)
Day IFN
Detected
Extensive
Chronic
GVHD
il) — No (nil) — No
50) 102 Yes (58) 102 Yes
3) 60 NR — Yes
1.7) 28 No (nil) — NA
7.7) 60 NR — Yes
il) — Yes (7.8) 60 Yes
2.7) 45 Yes (12.7) 65 Yes
il) — Yes (22.8) 62 Yes
1.8) 20 Yes (3) 40 Yes
il) — Yes (16.5) 150 Yes
— No — NA
5) 11 Yes (24) 39 Yes
il) — No (nil) — No
il) — No (nil) — No
8) 40 Yes (6.9) 40 Yes
il) — Yes (5) 41 Yes
il) — No (nil) — No
il) — No (nil) — No
— No — No
— No — NA
— No — NA
— No — NA
— No — NA
l increase seen before the onset of clinically detectable GVHD.nges in
reased
ranscr
old Inc
No (n
Yes (
Yes (
Yes (
Yes (
No (n
Yes (
No (n
Yes (
No (n
No
Yes (
No (n
No (n
Yes (
No (n
No (n
No (n
No
No
No
No
No
maximancreased TNF- transcription for the onset of extensive
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7hronic GVHD was also 100%, but with a much less
owerful negative predictive value of only 50%.
FN- Transcription
PCR for IFN- was performed in 20 patients. In 2
patients 3 and 5), no cDNA for IFN- or control 18S
ould be detected in the stored samples. Of the 16
ssessable allograft recipients, a 1.5-fold increase in
FN- transcription was seen in all 9 patients who
ventually developed chronic extensive GVHD (P 	
001), thus resulting in a positive predictive value of
00%. The positive predictive value of an increase in
FN- transcription for predicting acute GVHD,
owever, was 55%; only 4 of 9 patients with severe
cute GVHD showed an increase in IFN- transcrip-
ion (P 
 .20).
ISCUSSION
Although previous animal models have revealed a
ole for TNF- and IFN- in the development of
VHD, clinical correlations have been limited to the
easurement of cytokine levels present at the time of
linically evident GVHD. We have demonstrated for
he ﬁrst time that the serial measurement of TNF-
nd IFN- transcription levels in T cells isolated from
he peripheral blood of allogeneic SCT recipients can
igure 1. -Fold increase (y-axis) over baseline in TNF- and IFN-
n patient 7 after allogeneic SCT. The gray box in each panel shows
he period of severe (grade IV) gut GVHD with onset at day 65 and
esolution at day 100. BMT indicates bone marrow transplantation.ccurately predict the onset of acute and chronic G
10VHD, respectively, before it becomes clinically ev-
dent.
Using this approach, we correctly identiﬁed, by
hanges in TNF- transcription, the onset of acute
VHD in 8 of 9 patients with grade II to IV GVHD.
hanges in IFN- transcription were not as strongly
orrelated as TNF- for the onset of acute GVHD
ut were strongly predictive for the development of
xtensive chronic GVHD. Increased cytokine tran-
cription was not seen in recipients of autografts or
yngeneic SCT or in those who did not develop
VHD. This ﬁnding strongly supports previous ob-
ervations that inﬂammatory cytokines are predomi-
antly produced by alloreactive donor T cells [5].
We did not identify any relationship between the
nset of bacterial or viral infection and the detection
f increased cytokine transcription in our patients.
his may have been due to our use of isolated T cells
nly as the source of RNA, thus removing endotoxin-
timulated monocytes as a potential source of TNF-.
urthermore, patients undergoing autologous or syn-
eneic SCT were included as a control for changes in
ytokine transcription that may have been induced by
ucositis, neutropenic sepsis, or both. Even though
hese control patients developed these complications,
one revealed increased cytokine transcription. We
annot, however, fully discount the possibility that
nrecognized bacterial infection or viral reactivation
ay have promoted cytokine transcription and the
ubsequent onset of GVHD. Even if this were the
ase, it does not diminish the observed prospective
ink between increasing cytokine transcription and the
nset of GVHD.
The grade of GVHD did not correlate with the
egree of -fold increase measured (Table 2). This
bservation likely reﬂects the spacing of sample mon-
toring; that is, the true peak was missed, and that
irculating T cells are only functionally, but not quan-
itatively, representative of those that have trafﬁcked
o the sites of GVHD. These points notwithstanding,
ur ﬁndings reveal that prospective monitoring of
ytokine transcription by reverse transcription-PCR
an predict for GVHD onset and therefore allow for
ndividualization of immunosuppression therapy, in-
luding intensiﬁcation or delaying planned with-
rawal. We have observed that TNF- transcript lev-
ls decrease rapidly after the introduction of intensive
mmunosuppression for acute GVHD and allow po-
ential real-time measurement of therapy efﬁcacy
Figure 1). Conversely, patients who do not show
vidence of increased cytokine transcription during
mmunosuppression reduction can continue with-
rawal with the consequent saving of toxicity and drug
osts.
In addition to the clinical applicability, our ﬁnd-
ngs provide further insight into the pathogenesis of
VHD in the clinical setting. Mirroring the animal
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Prospective Monitoring of TNF- and IFN-
Bodel and in vitro data, it seems that TNF- pro-
uction is a major mechanism in the development of
evere acute GVHD, especially of the gut. It does
ot, however, seem to be the sole mechanism of
issue damage, because we observed 1 case (patient
7) of early-onset (day 14) severe isolated cutaneous
VHD in the absence of increased TNF transcrip-
ion. Conversely, IFN- production predicted for
xtensive chronic GVHD even in the absence of
ncreased TNF- transcription or prior acute
VHD. This separation of the 2 cytokines as pre-
ictive for different manifestations of GVHD indi-
ates that variations in T-cell stimuli during en-
raftment or cytokine production from different
-cell populations may lead to variations in the
anifestations of GVHD. These hypotheses remain
o be tested.
The central role of T-cell alloreactivity in the
evelopment of acute GVHD has led to a range of
trategies to completely deplete T cells with negative
r positive selection before SCT [18,19] or with
roadly active T cell–depleting antibody therapy such
s antithymocyte globulin [20] or anti-CD52 mono-
lonal antibody [21] shortly after transplantation.
hese approaches have signiﬁcantly reduced the inci-
ence and severity of GVHD, but at the cost of in-
reased risk from opportunistic infection and disease
elapse [22,23]. As a consequence, recent efforts have
oncentrated on the removal of alloreactive T cells
peciﬁcally while retaining most T cells within the
raft for immunologic reconstitution. These tech-
iques include negative selection of alloreactive T
ells by recognition of CD25 [24] and CD69 [25],
hanges in CD4 expression [26], or carboxy ﬂuoros-
einsuccinylester dilution [27]. These studies have
een limited to in vitro assays and animal models, and
ranslation of these techniques to clinical practice may
e costly and unwieldy, requiring access to highly
pecialized facilities that include sterile sorters and
ood manufacturing practice–grade clean rooms. The
ethod described in our study has been adapted from
ommercially available reagents and is readily appli-
able in most large hospital laboratories.
We conclude that serial monitoring of 2 key cy-
okines is an accurate and sensitive means of prospec-
ively identifying patients at imminent risk of devel-
ping GVHD and can be used to guide the diagnosis
f and preemptive therapy for GVHD.
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